[SARS-CoV-2 and neurological disorders: the revelance of biomarkers?]

Abstract

Soon after the pandemic, numerous publications described cases of neurological disorders associated with the SARS-CoV-2 infection. The range of neurological symptoms is becoming increasingly more extensive as the pandemic progresses. However, it is not yet well established whether the manifestations are due to direct viral damage to the nervous system or indirect consequences of the infection. This review presents an inventory of the biochemical markers studied in the context of neurological disorders related to SARS-CoV-2. By reflecting various physiopathological mechanisms, these biomarkers allow both a better understanding of the pathophysiology of Covid-19 and a contribution to the diagnosis of neurologic troubles; they could participate in the prognostic evaluation of patients.

Keywords: ACE2; ADEM; Acute Disseminated Encephalomyelitis; BHE; CK; CMH; Covid-19; EEG; Encéphalite/encéphalopathie avec lésion réversible du splénium du corps calleux; GFAP; Glial Fibrillary Acidic Protein; IRM; LCS; MERS; NSE; Nf-H; Nf-L; Nf-M; OMS; Organisation mondiale de la santé; PL; RAGE; Receptor For Advanced Glycation End-Products; SARS-CoV-2; SARS-Cov; SGB; SN; SNC; Severe Acute Respiratory Syndrome Coronavirus; TMPRSS2; TP; Transmembrane Serine Protease 2; barrière hémato-encéphalique; biomarkers; cerebrospinal fluid; chaînes légères de neurofilament; complexe majeur d’histocompatibilité; créatine kinase; imagerie par résonance magnétique; liquide cérébrospinal; neurofilaments lourds; neurofilaments moyens; neuroinflammation; neurological impairment; ponction lombaire; récepteur de l’enzyme de conversion de l’angiotensine 2; syndrome de Guillain-Barré; système nerveux; système nerveux central; taux de prothrombine; électro-encéphalogramme; énolase neurospécifique; β2-microglobuline; β2M.